Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Sanofi : France's Sanofi to help Johnson & Johnson manufacture COVID-19 vaccine

02/22/2021 | 06:22am EST
FILE PHOTO: Demonstration outside the Sanofi headquarters against job cuts in Paris

PARIS (Reuters) - French healthcare company Sanofi will provide COVID-19 vaccine manufacturing support to U.S. peer Johnson & Johnson, Sanofi said on Monday.

Once authorized, Sanofi will provide Johnson & Johnson access to the established infrastructure and expertise of its vaccine manufacturing plant in Marcy l'Etoile, France, to formulate and fill vials of Johnson & Johnson's Janssen COVID-19 vaccine candidate in 2021 at a rate of approximately 12 million doses per month.

(Reporting by Sudip Kar-Gupta; editing by Jason Neely)


© Reuters 2021
All news about SANOFI
09:26aSANOFI  : - CHMP recommends approval of Sarclisa in combination with carfilzomib..
AQ
01:33aPRESS RELEASE : Evotec and Chinook Therapeutics enter into strategic collaborati..
DJ
02/26European ADRs Move Sharply Lower in Friday Trading
MT
02/26SANOFI  : EU Clears Sanofi's Sarclisa Combination Therapy for Relapsed Multiple ..
MT
02/26SANOFI  : CHMP recommends approval of Sarclisa® (isatuximab) in combination with..
PU
02/25GSK narrows focus on elderly in trial to treat pneumonia from COVID-19
RE
02/25PRESS RELEASE  : Pfizer and BioNTech Initiate a -2-
DJ
02/24SANGAMO THERAPEUTICS  : Swings to Q4 Net Loss of $0.29 a Share on Lower Revenue,..
MT
02/24SANOFI  : No Unpatentability In A Successful Motion To Amend
AQ
02/23Health Care Ticks Down As Investors Await Vaccine Updates -- Health Care Roun..
DJ
More news
Financials
Sales 2020 36 401 M 43 865 M 43 865 M
Net income 2020 12 136 M 14 624 M 14 624 M
Net Debt 2020 7 987 M 9 625 M 9 625 M
P/E ratio 2020 7,89x
Yield 2020 4,20%
Capitalization 96 013 M 116 B 116 B
EV / Sales 2020 2,86x
EV / Sales 2021 2,78x
Nbr of Employees 100 409
Free-Float 88,9%
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | MarketScreener
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 100,19 €
Last Close Price 76,42 €
Spread / Highest target 53,1%
Spread / Average Target 31,1%
Spread / Lowest Target -8,40%
EPS Revisions
Managers and Directors
NameTitle
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-3.68%115 225
JOHNSON & JOHNSON0.69%416 541
ROCHE HOLDING AG-3.58%280 845
NOVARTIS AG-6.53%194 250
ABBVIE INC.0.55%190 256
PFIZER INC.-9.02%186 852